(PR-inside.com) http://www.alnylam.com - Alnylam Pharmaceuticals, Inc. Investors: Cynthia Clayton, 617-551-8207 or Media: Yates Public Relations Kathryn Morris, 845-635-9828 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has appointed John A. Schmidt, Jr., M.D. to the position of Chief Scientific Officer. In this role, Dr. Schmidt will play a critical role in leading Alnylam's research and drug discovery activities, and will report to John Maraganore, Alnylam's Chief Executive Officer. 'We are thrilled that Jack is joining Alnylam at such an exciting time in the growth of our company,' said John Maraganore, Chief Executive Officer of ..
More...
More...